In the context of the Risk Management Plan (RMP), as requested from Addmedica by the EMEA, to collect information about long-term safety of Siklos® (hydroxycarbamide) when used in patients with Sickle Cell Disease.
Study Type
OBSERVATIONAL
Enrollment
1,906
% of Patient-years With Malignancies
Time frame: During the follow-up of participant, up to 10 years
% of Patient-years With Skin Ulcerations
Patients with at least one skin ulceration
Time frame: During the follow-up of participant, up to 10 years
% of Patient-years With Myelosuppressions
Patients with at least one myelosuppression
Time frame: During the follow-up of participant, up to 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU d'Amiens - Picardie - Site sud
Amiens, France
Centre Hospitalier Robert Ballanger, pédiatrie et néonatalogie
Aulnay-sous-Bois, France
Hôpital Avicenne; médecine interne
Bobigny, France
Hôpital Jean Verdier; médecine interne
Bondy, France
Hôpital Jean Verdier; pédiatrie
Bondy, France
CHU Bordeaux, urgences pédiatriques
Bordeaux, France
Hôpital Saint-André
Bordeaux, France
CHU Estaing, pédiatrie
Clermont-Ferrand, France
Hôpital Louis Mourier; pédiatrie
Colombes, France
Hôpital Louis Mourier; service de pédiatrie
Colombes, France
...and 50 more locations